Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 12.65 | 29.81 | 25.03 | 29.65 | 11.54 | 11.13 | 9.86 | 16.93 | 21.40 | 31.51 | 12.23 | 27.55 | 19.18 | 15.37 | 15.10 | 29.36 | 12.75 | 70.06 | 67.31 | — | — |
| — | +167.9% | +153.9% | +75.1% | -46.1% | -64.7% | -19.4% | -38.6% | +11.6% | +104.9% | -19.0% | -6.2% | +50.5% | -78.1% | -77.6% | — | — | +94.0% | +530.1% | — | — | |
| P/S Ratio | 2.18 | 4.81 | 5.03 | 4.42 | 1.92 | 1.88 | 2.12 | 1.70 | 2.24 | 2.36 | 2.11 | 2.18 | 2.29 | 2.46 | 2.51 | 2.37 | 1.90 | 2.33 | 2.31 | 1.87 | 2.30 |
| — | +155.2% | +137.7% | +159.3% | -14.3% | -20.0% | +0.5% | -21.9% | -2.3% | -4.2% | -16.2% | -7.9% | +20.6% | +5.3% | +8.9% | +27.0% | -17.5% | -4.0% | +1.5% | -16.6% | -15.9% | |
| P/B Ratio | 2.65 | 5.88 | 6.50 | 5.63 | 2.54 | 2.43 | 2.80 | 2.48 | 2.98 | 3.08 | 2.85 | 2.68 | 2.83 | 3.00 | 3.05 | 2.87 | 2.37 | 2.80 | 2.89 | 2.28 | 2.28 |
| — | +141.8% | +132.2% | +126.5% | -14.8% | -21.0% | -1.8% | -7.3% | +5.2% | +2.6% | -6.7% | -6.5% | +19.2% | +7.3% | +5.6% | +25.6% | +4.2% | -45.1% | -37.2% | -46.2% | -57.0% | |
| P/FCF | 14.79 | 34.65 | 42.27 | 49.79 | 8.56 | 18.62 | 10.49 | 13.00 | 15.00 | 12.61 | 30.31 | 18.29 | 11.78 | 22.72 | 16.43 | 14.40 | 11.47 | 35.66 | 9.16 | 32.00 | 21.47 |
| — | +86.1% | +303.0% | +282.9% | -43.0% | +47.7% | -65.4% | -28.9% | +27.3% | -44.5% | +84.5% | +27.1% | +2.7% | -36.3% | +79.5% | -55.0% | -46.6% | +7.7% | -19.3% | +141.3% | +33.0% | |
| EV / EBITDA | 7.81 | 15.86 | 14.89 | 16.60 | 6.88 | 6.88 | 7.14 | 11.47 | 9.45 | 9.22 | 7.64 | 12.47 | 9.97 | 9.14 | 8.31 | 13.76 | 10.50 | 16.52 | 14.91 | 15.01 | 25.99 |
| — | +130.6% | +108.5% | +44.8% | -27.2% | -25.4% | -6.5% | -8.0% | -5.2% | +0.9% | -8.0% | -9.4% | -5.1% | -44.7% | -44.3% | -8.3% | -59.6% | +35.2% | +103.2% | +73.9% | +137.3% | |
| EV / EBIT | 11.07 | 24.98 | 19.40 | 24.03 | 9.60 | 9.45 | 9.44 | 15.05 | 16.23 | 13.07 | 10.39 | 23.79 | 15.78 | 13.54 | 12.81 | 28.80 | 21.48 | 56.12 | 36.67 | — | — |
| — | +164.5% | +105.6% | +59.7% | -40.8% | -27.8% | -9.2% | -36.7% | +2.8% | -3.4% | -18.9% | -17.4% | -26.5% | -75.9% | -65.1% | — | — | +166.3% | +254.8% | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.9% | 83.6% | 82.5% | 79.9% | 81.6% | 82.9% | 83.5% | 81.7% | 77.3% | 83.1% | 82.5% | 80.8% | 81.8% | 82.8% | 82.5% | 74.1% | 72.8% | 72.2% | 69.2% | 61.5% | 61.9% |
| — | +0.9% | -1.2% | -2.2% | +5.5% | -0.3% | +1.2% | +1.1% | -5.5% | +0.4% | +0.0% | +9.0% | +12.2% | +14.8% | +19.2% | +20.5% | +17.6% | -1.6% | -7.2% | -22.6% | -21.8% | |
| Operating Margin | 23.4% | 20.6% | 27.8% | 19.2% | 23.6% | 24.3% | 27.0% | 13.7% | 15.5% | 21.2% | 24.6% | 10.3% | 17.0% | 21.5% | 23.4% | 9.8% | 11.3% | 5.0% | 7.7% | -2.4% | -17.0% |
| — | -15.2% | +2.7% | +40.5% | +51.9% | +14.3% | +10.1% | +33.2% | -8.7% | -1.3% | +4.9% | +5.1% | +50.0% | +329.9% | +204.0% | +501.5% | +166.8% | -63.5% | -70.2% | -112.1% | -195.3% | |
| Net Margin | 17.5% | 16.3% | 20.1% | 15.0% | 16.7% | 16.9% | 21.5% | 10.1% | 10.5% | 14.9% | 17.2% | 8.0% | 12.0% | 15.9% | 16.6% | 8.0% | 14.9% | 3.3% | 3.4% | -2.9% | -16.7% |
| — | -3.8% | -6.1% | +48.9% | +58.3% | +13.8% | +24.9% | +26.2% | -11.9% | -6.5% | +3.7% | -0.7% | -19.9% | +376.5% | +389.0% | +378.3% | +189.2% | -50.0% | -84.1% | -121.2% | -270.0% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.9% | 5.1% | 6.4% | 4.9% | 5.6% | 5.7% | 7.1% | 3.7% | 3.6% | 5.0% | 5.7% | 2.5% | 3.7% | 5.0% | 4.9% | 2.5% | 4.6% | 1.0% | 1.0% | -0.9% | -5.9% |
| — | -10.0% | -9.9% | +33.8% | +57.0% | +14.1% | +25.1% | +46.1% | -3.5% | +0.7% | +14.9% | +0.7% | -20.2% | +398.7% | +384.9% | +384.8% | +177.6% | -72.7% | -90.2% | -112.7% | -225.1% | |
| ROA | 9.4% | 2.2% | 2.7% | 2.0% | 2.2% | 2.2% | 2.8% | 1.4% | 1.4% | 1.9% | 2.1% | 1.0% | 1.4% | 1.9% | 1.9% | 0.9% | 1.7% | 0.4% | 0.4% | -0.3% | -1.8% |
| — | -2.6% | -2.6% | +41.8% | +63.5% | +20.1% | +29.4% | +47.5% | -4.3% | -0.9% | +14.8% | +3.0% | -17.0% | +414.4% | +397.3% | +389.5% | +194.1% | -53.9% | -84.2% | -121.1% | -274.8% | |
| ROIC | 14.9% | 3.1% | 4.3% | 3.1% | 3.8% | 3.8% | 4.1% | 2.3% | 2.4% | 3.2% | 3.7% | 1.5% | 2.4% | 3.0% | 3.2% | 1.4% | 1.5% | 0.7% | 1.0% | -0.3% | -2.7% |
| — | -17.6% | +5.0% | +35.9% | +61.3% | +20.6% | +11.8% | +52.4% | -1.3% | +5.2% | +17.4% | +10.3% | +54.6% | +354.5% | +200.5% | +500.7% | +156.9% | -78.7% | -79.6% | -108.6% | -186.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.61 | 0.64 | 0.72 | 0.61 | 0.71 | 0.73 | 0.77 | 0.74 | 0.77 | 0.85 | 0.92 | 0.73 | 0.77 | 0.80 | 0.88 | 0.79 | 0.83 | 0.82 | 0.86 | 0.78 | 0.80 |
| — | -12.7% | -7.2% | -17.3% | -8.1% | -13.5% | -16.3% | +0.8% | +0.7% | +6.2% | +4.7% | -7.4% | -7.9% | -2.9% | +2.8% | +0.7% | +4.2% | -53.1% | -38.6% | -39.9% | -51.3% | |
| Debt / EBITDA | 1.53 | 6.32 | 6.04 | 6.62 | 6.36 | 6.71 | 6.40 | 10.95 | 8.05 | 8.33 | 7.91 | 11.18 | 8.83 | 8.00 | 7.78 | 12.45 | 11.36 | 15.57 | 14.22 | 16.20 | 28.65 |
| — | -5.7% | -5.5% | -39.6% | -20.9% | -19.5% | -19.1% | -2.0% | -8.9% | +4.2% | +1.7% | -10.2% | -22.3% | -48.7% | -45.3% | -23.2% | -60.3% | +6.5% | +90.1% | +81.6% | +152.9% | |
| Current Ratio | 0.94 | 0.89 | 0.91 | 0.94 | 0.88 | 0.86 | 0.90 | 0.93 | 0.93 | 0.89 | 0.89 | 0.82 | 0.79 | 0.87 | 0.90 | 0.86 | 0.81 | 0.96 | 1.00 | 1.16 | 1.13 |
| — | +2.7% | +1.3% | +1.2% | -5.6% | -2.9% | +1.3% | +13.0% | +18.4% | +2.7% | -1.1% | -4.5% | -3.3% | -9.7% | -10.1% | -26.0% | -27.9% | -21.9% | +14.4% | +20.7% | +17.7% | |
| Quick Ratio | 0.72 | 0.67 | 0.71 | 0.72 | 0.69 | 0.67 | 0.70 | 0.74 | 0.71 | 0.69 | 0.70 | 0.64 | 0.60 | 0.67 | 0.70 | 0.68 | 0.61 | 0.67 | 0.66 | 0.76 | 0.68 |
| — | -0.5% | +1.7% | -1.8% | -3.9% | -3.0% | -0.8% | +14.7% | +18.5% | +2.4% | +0.7% | -5.6% | -1.2% | +0.1% | +5.3% | -10.9% | -10.8% | -33.5% | -1.7% | -0.0% | -10.6% | |
| Interest Coverage | 8.32 | 7.43 | 10.96 | 6.57 | 8.47 | 8.12 | 10.75 | 4.88 | 5.00 | 6.41 | 7.78 | 3.02 | 5.21 | 5.84 | 7.20 | 3.26 | 3.72 | 1.79 | 2.65 | -1.04 | -4.97 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AZN stock.
AstraZeneca PLC's current P/E is 12.6x. The average P/E over the last 4 quarters is 24.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
AstraZeneca PLC's current operating margin is 23.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking AstraZeneca PLC's business trajectory between earnings reports.